Not exact matches
The Albert and Mary Lasker Foundation announced yesterday that it was presenting its prestigious 2017 Lasker - DeBakey
Clinical Medical Research Award to a pair of National Cancer Institute
researchers, Douglas Lowy and John Schiller, who created a
vaccine to prevent human papilloma virus, or HPV, from taking hold in the body.
Researchers at Oregon Health & Science University are currently looking for volunteers that can be tested during an upcoming
clinical trial for a
vaccine that may cure HIV, the virus that causes AIDS.
An experimental
vaccine to prevent the mosquito - borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early - stage
clinical trial conducted by
researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
A 2007
clinical trial of a
vaccine made by Merck was stopped when
researchers found that, in fact, more people who received the active
vaccine (49) than the placebo (33) had contracted HIV.
As a new generation of
vaccines begin
clinical trials,
researchers wonder if they've finally got this killer beat.
The
researchers hope that understanding the level of virus needed for transmission of infection will provide a useful reference point for the development of experimental drugs and
vaccines and could be used to inform the endpoints for
clinical trials evaluating such interventions.
«New malaria
vaccine effective in
clinical trial:
Researchers achieve protection of up to 100 percent using fully viable malaria parasites.»
According to the
researchers continued surveillance of HPV vaccination is necessary to identify
clinical benefits, particularly given the low rate of
vaccine uptake and completion and vaccination of many young women after sexual debut.
University of Tübingen
researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a
clinical trial that a new
vaccine for malaria called Sanaria ® PfSPZ - CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of
vaccine.
When a biotech company called Sanaria presented the results of a
clinical study of its unconventional malaria
vaccine last year, many
researchers were disappointed.
Clinical researchers at the University of Rochester administered the
vaccines and monitored volunteers.
In the new issue of IAVI Report we wrote about how
researchers at the AIDS
Vaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially effective HIV prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combi
Vaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting
clinical trials to test partially effective HIV prevention strategies, including HIV
vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combi
vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combination.
This
vaccine prototype is today being studied by Cancer Center
researchers in
clinical trials for kidney, prostate, and pancreatic cancers.
«After two years of analyzing the results of the largest AIDS
vaccine clinical trial ever held — called RV144 —
researchers say they have found two ways the immune system can respond, which could predict whether those inoculated will be protected or are more likely to become infected with HIV.»